Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study
This study is ongoing, but not recruiting participants.
Sponsored by: Memorial Sloan-Kettering Cancer Center
Information provided by: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00597532
  Purpose

To Test Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue using a Randomized Placebo Controlled Study.

Objectives:

  • To determine (by immunohistochemistry) whether specific cellular markers and gene products associated with breast carcinoma can be altered by soy therapy.
  • To identify genes that can be altered by soy therapy in normal and neoplastic breast tissues by unbiased gene expression analysis using microarrays.
  • To compare specific cellular markers and pathways (immunohistochemistry), and gene expression using microarrays in normal and cancerous breast tissue.

Condition Intervention Phase
Breast Cancer
Dietary Supplement: Soy
Dietary Supplement: Milk
Phase 0

Genetics Home Reference related topics: breast cancer
MedlinePlus related topics: Breast Cancer Cancer Dietary Supplements
Drug Information available for: Proteins, soy
U.S. FDA Resources
Study Type: Interventional
Study Design: Diagnostic, Randomized, Single Blind (Subject), Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study

Further study details as provided by Memorial Sloan-Kettering Cancer Center:

Primary Outcome Measures:
  • The primary outcome of the study is comparison of the change in proliferation (Ki67) and apoptosis (TUNEL) in cancerous tissue between the 2 groups. [ Time Frame: Conclusion of the study ] [ Designated as safety issue: No ]

Enrollment: 140
Study Start Date: August 2002
Estimated Study Completion Date: August 2009
Estimated Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
soy (soy protein supplementation 50 grams/day)
Dietary Supplement: Soy
soy (soy protein supplementation 50 grams/day)
2: Placebo Comparator
milk protein supplementation 50 grams/day
Dietary Supplement: Milk
placebo (milk protein supplementation 50 grams/day)

Detailed Description:

Patient Population:

Pre and post menopausal women with breast cancer diagnosed by core needle biopsy scheduled to undergo breast cancer resection for an invasive carcinoma.

Objectives:

  • To determine (by immunohistochemistry) whether specific cellular markers and gene products associated with breast carcinoma can be altered by soy therapy.
  • To identify genes that can be altered by soy therapy in normal and neoplastic breast tissues by unbiased gene expression analysis using microarrays.
  • To compare specific cellular markers and pathways (immunohistochemistry), and gene expression using microarrays in normal and cancerous breast tissue.

Study Design and Intervention Plan:

  • Eligible patients will be consented at the time of visit with MSKCC breast surgeon and randomized to receive soy (soy protein supplementation 50 grams/day), or placebo (milk protein supplementation 50 grams/day) over the period until their surgery.
  • The diagnostic biopsy (already available at time of appointment with MSKCC surgeon) will be analyzed by immunohistochemistry for proliferation (Ki67) and apoptosis (TUNEL). Additional immunohistochemistry will include HER2, TP53, cyclin D1, p27, BCL2, ER and PR.
  • Excision of the breast carcinoma (lumpectomy or mastectomy) will proceed in standard fashion.
  • The post-therapy excision specimen will be processed in a standard fashion. Pathologic features, margin status, and tumor size will be assessed by a light microscopic examination of histological sections. In addition to this routine processing, immunohistochemistry assays for proliferation (Ki67), apoptosis (TUNEL), HER2, TP53, cyclin D1, p27, BCL2, ER, and PR will be performed. For correlative biological studies pathologists will select approximately .5 cubic mm representative sections of the neoplastic tissues and normal adjacent breast tissue, which will be snap frozen for gene expression analysis using microarrays.
  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Informed consent obtained
  • Breast mass > .5 cm (determined by mammogram, ultrasound, MRI, or palpable criteria)
  • Core biopsy diagnosis of invasive carcinoma of the breast

Exclusion Criteria:

  • History of active malignancy within previous two years (except for non-melanoma skin cancer and history of breast cancer).
  • Regular soy consumption (consumption of more than 3 serving of soy or soy products/supplements per week)
  • Allergy to soy or milk protein
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00597532

Locations
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Investigators
Principal Investigator: Moshe Shike, MD Memorial Sloan-Kettering Cancer Center
  More Information

Related Info  This link exits the ClinicalTrials.gov site

Responsible Party: Memorial Sloan-Kettering Cancer Center ( Moshe Shike, M.D. )
Study ID Numbers: 02-062
Study First Received: December 26, 2007
Last Updated: January 10, 2008
ClinicalTrials.gov Identifier: NCT00597532  
Health Authority: United States: Institutional Review Board

Keywords provided by Memorial Sloan-Kettering Cancer Center:
Breast Cancer
Soy
Milk
Supplementation
02-062

Study placed in the following topic categories:
Skin Diseases
Breast Neoplasms
Breast Diseases

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 16, 2009